Tiago Fleming Outeiro

Summary

Publications

  1. ncbi Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
  2. ncbi Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
  3. ncbi Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA
    Biochem Biophys Res Commun 351:631-8. 2006
  4. ncbi Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease
    Jean Christophe Rochet
    Center for Neurologic Diseases, Brigham and Women s Hospital, Department of Neurology, Harvard Medical School, Cambridge, MA 02139, USA
    J Mol Neurosci 23:23-34. 2004
  5. ncbi Yeast cells provide insight into alpha-synuclein biology and pathobiology
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Science 302:1772-5. 2003
  6. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
  7. ncbi Yeast as a drug discovery platform in Huntington's and Parkinson's diseases
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, MIT, Cambridge, MA, USA
    Biotechnol J 1:258-69. 2006
  8. ncbi Formation of toxic oligomeric alpha-synuclein species in living cells
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America
    PLoS ONE 3:e1867. 2008

Collaborators

Detail Information

Publications8

  1. ncbi Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models
    Tiago Fleming Outeiro
    Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 3300, 16th St, Charlestown, MA 02129 4404, USA
    Biochem Biophys Res Commun 357:596-602. 2007
    ..Further, our results suggest a rationale for the development of highly potent, bio-available, brain-penetrable PARP-1 inhibitors to provide therapeutic benefits for Parkinson's patients...
  2. ncbi Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
    ..Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging...
  3. ncbi Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA
    Biochem Biophys Res Commun 351:631-8. 2006
    ..In addition, intracellular inclusions were immunopositive for endogenous Hsp27, and overexpression of this protein reduced aSyn aggregation in a cell culture model...
  4. ncbi Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease
    Jean Christophe Rochet
    Center for Neurologic Diseases, Brigham and Women s Hospital, Department of Neurology, Harvard Medical School, Cambridge, MA 02139, USA
    J Mol Neurosci 23:23-34. 2004
    ..These variants might be useful to test whether membrane binding by alpha-synuclein is necessary for neurodegeneration in transgenic animal models of PD...
  5. ncbi Yeast cells provide insight into alpha-synuclein biology and pathobiology
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Science 302:1772-5. 2003
    ..This readily manipulable system provides an opportunity to dissect the molecular pathways underlying normal alpha-synuclein biology and the pathogenic consequences of its misfolding...
  6. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
    ....
  7. ncbi Yeast as a drug discovery platform in Huntington's and Parkinson's diseases
    Tiago Fleming Outeiro
    Whitehead Institute for Biomedical Research, MIT, Cambridge, MA, USA
    Biotechnol J 1:258-69. 2006
    ..In addition, we discuss new yeast-based techniques for screening candidate therapeutic compounds for Huntington's and Parkinson's diseases...
  8. ncbi Formation of toxic oligomeric alpha-synuclein species in living cells
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America
    PLoS ONE 3:e1867. 2008
    ..However, to date, oligomeric species have not been identified in living cells...